Antitumor activities of recombinant human interferon (IFN)-λ1 in vitro and in xenograft models in vivo for colon cancer

Cancer Letters

Volumn 311, Issue 2, 2011, Pages 141-151

  Hui, Xiwu ^a   Chen, Hong ^a   Zhang, Shenghua ^b   Ma, Xiaoli ^a   Wang, Xin ^a   Huang, Bingren ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Antitumor; Cancer therapy; Human colon cancer; RhIFN 1; Xenograft models

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 29; RECOMBINANT INTERLEUKIN 29; STAT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE I, RECOMBINANT; MICE; MICE, INBRED BALB C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053133357     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.004     Document Type: Article

References (36)

1. Kotenko S.V., Gal agber G., Baurin W., Lewis-Antes Anita, Shen Meiling, Shah Nital K., Langer Jerome A., Sheikh Faruk, Dickensheets Harold, Donnelly Raymond P. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Inmmnol. 2003, 4:69-77.
2. Sheppard P., Kindsvogel W., Xu W., Henderson Katherine, Schlutsmeyer Stacy, Whitmore Theodore E., Kuestner Rolf, Garrigues Ursula, Birks Carl, Roraback Jenny, Ostrander Craig, Dong Dennis, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003, 4:63-68.
3. Gad Hans Henrik, Dellgren Christoffer, Hamming Ole J., Vends Susanne, Paludan Søren R., Hartmann Rune Interferon-λs functionally an interferon but structurally related to the interleukin-10 Family. J. Biol. Chem. 2009, 284:20869-20875.
4. Lasfar Ahmed, Lewis-Antes Anita, Smirnov Sergey V., Anantha Shubha, Abushahba Walid, Tian Bin Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res. 2006, 66:4468-4477.
5. Chen Q., Carroll H.P., Gadina M. The newest interleukins: recent additions to the ever-growing cytokine family. Vitam. Horm. 2006, 74:207-228.
6. Renanld J.C. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat. Rev. Immunol. 2003, 3:667-676.
7. Vilcek J. Novel interferons. Nat. Imnmnol. 2003, 4:8-9.
8. Dumoutier Laure, Tounsi Amel, Michiels Thomas, Sommereyns Caroline, Kotenko Sergei V., Renauld Jean-Christophe Role of interleukin IL-28 receptor tyrosine residues for antival and antiproliferative activity of IFN-λ1/interferon-λ1. J. Biol. Chem. 2004, 279:32269-32274.
9. Dumoutier Laure, Lejeune Diane, Hor Simon, Fickenscher Helmut, Renauld Jean-Christophe Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem. J. 2003, 370(pt2):391-396.
10. Li W.A. Regulation of apoptosis by type III interferons. Cell Prolif. 2008, 41:960-979.
11. Maher Stephen G., Sheikh Faruk, Scarzello Anthony J., Romero-Weaver Ana L., Baker Darren P., Donnelly Raymond P., Gamero Ana M. IFN-α and IFN-λ differ in their antiproliferative effects and uration of JAK/STAT signaling activity. Cancer Biol. Ther. 2008, 7:1109-1115.
12. Zitzmann Kathrin, Brand Stephan, Baehs Sebastian, Göke Burkhard, Meinecke Jennifer, Spöttl Gerald, Meyer Heinrich, Auernhammer Christoph J. Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells. Biochem. Biophys. Res. Commun. 2006, 344:1334-1341.
13. Li Quanhai, Kawamura Kiyoko, Ma Guangyu, Iwata Fumi, Numasaki Muneo, Suzuki Nobuo, Shimada Hideaki, Tagawa Masatoshi Interferon-λ induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces antitumour effects in combination with anti-cancer agents. Eur. J. Cancer 2010, 46:180-190.
14. Sato Atsuko, Ohtsuki Mamitaro, Hata Megumi, Kobayashi Eiji, Murakami Takashi Antitumor activity of IFN-λ in murine tumor models. J. Immunol. 2006, 176:7686-7694.
15. Yun Fei Xie, Hong Chen, Bing Ren Huang Expression, purification and characterization of human IFN-λ1 in Pichia pastoris. J. Biotechnol. 2007, 129:472-480.
16. Witte K., Gruetz G., Volk H.-D., Looman A.C., Asadullah K., Sterry W., Sabat R., Wolk K. Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Gen. Immun. 2009, 10:702-714.
17. Zhou Yu, Chen Hong, Ma Xiao-Li, Xie Hai-Jun, Wang Cun-Lin, Zhang Sheng-Hua, Wang Xin, Huang Bing-Ren Fusion protein of adenovirus E4orf4 and human epidermal growth factor inhibits tumor cell growth. Int. J. Cancer 2009, 125:1186-1192.
18. Saleh M.N., Raisch K.P., Stackhouse M.A., Grizzle W.E., Bonner J.A., Mayo M.S., Kim H.G., Meredith R.F., Wheeler R.H., Buchsbaum D.J. Combined modality therapy of A431 human epidermoid cancer using anti-EGFR antibody C225 and radiation. Cancer Biother. Radiopharm. 1999, 14:451-463.
19. Skipper Joni B., McNally Lacey R., Rosenthal Eben L., Wang Wenquan, Buchsbaum Donald J. In vivo efficacy of marimastat and chemoradiation in head and neckca ncer xenografts. ORL J. Otorhinolaryngol. Relat. Spec. 2009, 71:1-5.
20. Dean Nichole R., Robert Newman J., Helman Emily E. Anti-EMMPRINmonoclonal antibody as a Novel agent for therapy of head and neck cancer. Clin Cancer Res. 2009, 15:4058-4065.
21. Mohammed A. Aleskandarany, Emad A. Rakha, R. Douglas Macmillan, Desmond G. Powe, Ian O. Ellis, Andrew R. Green, MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups, Breast Cancer Res. Treat. July 11 (2010) PMID: 20623333.
22. Floris Giuseppe, Debiec-Rychter Maria, Sciot Raf High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res. 2009, 15(12):4066-4076.
23. Robert Newman J., Bohannon Isaac A., Zhang Wenyue, Skipper Joni B., Grizzle William E., Rosenthal Eben L. Modulation of tumor cell growth in vivo by extracellular matrix metalloprotease inducer. Arch. Otolaryngol. Head NeckSurg. 2008, 134:1218-1224.
24. Menon Jyotsana, Soto-Pantoja David R., Callahan Michael F., Mark Cline J., Ferrario Carlos M., Ann Tallant E., Gallagher Patricia E. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res. 2007, 67:2809-2815.
25. Abushahba W., Balan M., Castaneda I., Yuan Y., Reuhl K., Raveche E., de la Torre A., Lasfar A., Kotenko S.V. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol. Immunother. 2010, 59:1059-1071.
26. Ueda S., Tsuda H., Saeki T., Omata J., Osaki A., Shigekawa T., Ishida J., Tamura K., Abe Y., Moriya T., Yamamoto J. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer 2010, PMID: 20617404.
27. Kirkwood John M., Tarhini Ahmad A., Panelli Monica C., Moschos Stergios J., Zarour Hassane M., Butterfield Lisa H., Gogas Helen J. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 2008, 26:3445-3455.
28. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat. Rev. 2006, 32:365-376.
29. Sievert W. Management issues in chronic viral hepatitis: hepatitis C. J. Gastroenterol. Hepatol. 2002, 17:415-422.
30. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem. 2007, 282:20047-20051.
31. Muir Andrew J., Shiffman Mitchell L., Zaman Atif, Yoffe Boris, Torre Andrew de la, Flamm Steven, Gordon Stuart C., Marotta Paul, Vierling John M., Lopez-Talavera Juan Carlos, Byrnes-Blake Kelly, Fontana David Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010, 52:822-832.
32. Pedder S.C. Pegylation of interferon alfa: structural and pharmacokinetic properties. Semin. Liver Dis. 2003, 23(Suppl 1):19-22.
33. Cho Okki, Hon Seung Ho, Kim Jung Sik, Yoon Joon-Kee, Kim Kyongmin, Chwae Yong-Joon, et al. IFN-λ endocytosis and IFN-λ responsive promoter activation are dependent on cholesterol. Cytokine 2010, 51:93-100.
34. Dai Jihong, Megjugorac Nicholas J., Gallagher Grant E., Yu Raymond Y.L., Gallagher Grant IFN-λ1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 2009, 113:5829-5838.
35. Mennechet F.J., Uzé G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006, 107:4417-4423.
36. Jordan W.J., Eskdale J., Srinivas S., Pekarek V., Kelner D., Rodia M., Gallagher G. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Gen. Immun. 2007, 8:254-261.